Literature DB >> 8755164

Analysis of developmental switching in transgenic mice with 5' and 3' deletions in the human beta globin gene.

K P Anderson1, C B Kern, S C Crable, J C Neumann, J B Lingrel.   

Abstract

Our interest in the cis-acting elements that promote the up-regulation of the beta globin gene has led to a systematic deletion analysis of portions of the beta globin gene in the context of the HS2 and gamma globin gene using transgenic mice. In constructs that delete the 5' region to only 265 bp, high-level, erythroid-specific expression was observed. Further deletion to 122 bp, however, results in significantly reduced expression levels. A substitution of a minilocus control region for the single HS2 site was also produced, resulting in increased beta globin expression over that seen with the HS2 alone. These results are consistent with the presence of an enhancer-like element between -122 and -265. In addition, a construct in which the entire beta globin gene promoter was replaced by a thymidine kinase promoter was tested. Interestingly, no expression was detected in these transgenic mice. This may indicate the requirement for an erythroid-specific promoter to drive this gene. Finally, the 3' region of the beta globin gene was deleted in order to examine the effect of a previously defined 3' enhancer region. With deletion of this region, the expression of the human beta globin gene in transgenic mice is unchanged relative to the parental constructs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755164     DOI: 10.1007/bf01972878

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  39 in total

1.  A 3' enhancer contributes to the stage-specific expression of the human beta-globin gene.

Authors:  M Trudel; F Costantini
Journal:  Genes Dev       Date:  1987-11       Impact factor: 11.361

2.  Protein-DNA interactions in vivo of an erythroid-specific, human beta-globin locus enhancer.

Authors:  P M Reddy; C K Shen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

3.  Individual stage selector element mutations lead to reciprocal changes in beta- vs. epsilon-globin gene transcription: genetic confirmation of promoter competition during globin gene switching.

Authors:  K P Foley; J D Engel
Journal:  Genes Dev       Date:  1992-05       Impact factor: 11.361

4.  The human beta-globin gene 3' enhancer contains multiple binding sites for an erythroid-specific protein.

Authors:  L Wall; E deBoer; F Grosveld
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

5.  Molecular analysis of the human beta-globin locus activation region.

Authors:  W C Forrester; U Novak; R Gelinas; M Groudine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Developmental regulation of beta-globin gene switching.

Authors:  O R Choi; J D Engel
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

7.  A dominant control region from the human beta-globin locus conferring integration site-independent gene expression.

Authors:  D Talbot; P Collis; M Antoniou; M Vidal; F Grosveld; D R Greaves
Journal:  Nature       Date:  1989-03-23       Impact factor: 49.962

8.  Analysis of transcriptional regulatory signals of the HSV thymidine kinase gene: identification of an upstream control region.

Authors:  S L McKnight; E R Gavis; R Kingsbury; R Axel
Journal:  Cell       Date:  1981-08       Impact factor: 41.582

9.  Human fetal to adult hemoglobin switching: changes in chromatin structure of the beta-globin gene locus.

Authors:  M Groudine; T Kohwi-Shigematsu; R Gelinas; G Stamatoyannopoulos; T Papayannopoulou
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

10.  Identification of a stage selector element in the human gamma-globin gene promoter that fosters preferential interaction with the 5' HS2 enhancer when in competition with the beta-promoter.

Authors:  S M Jane; P A Ney; E F Vanin; D L Gumucio; A W Nienhuis
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.